APA (7th ed.) Citation

Schad, F., Thronicke, A., Hofheinz, R., Klein, R., Grabowski, P., Oei, S. L., . . . Grah, C. (2024). Immune checkpoint blockade combined with abnobaViscum therapy is linked to improved survival in advanced or metastatic non-small-cell lung cancer patients: A registry study in accordance with the ESMO guidance for reporting real-world evidence. Pharmaceuticals, 17(12), . https://doi.org/10.3390/ph17121713

Chicago Style (17th ed.) Citation

Schad, Friedemann, Anja Thronicke, Ralf-Dieter Hofheinz, Reinhild Klein, Patricia Grabowski, Shiao Li Oei, Hannah Wüstefeld, and Christian Grah. "Immune Checkpoint Blockade Combined with AbnobaViscum Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-small-cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-world Evidence." Pharmaceuticals 17, no. 12 (2024). https://doi.org/10.3390/ph17121713.

MLA (9th ed.) Citation

Schad, Friedemann, et al. "Immune Checkpoint Blockade Combined with AbnobaViscum Therapy Is Linked to Improved Survival in Advanced or Metastatic Non-small-cell Lung Cancer Patients: A Registry Study in Accordance with the ESMO Guidance for Reporting Real-world Evidence." Pharmaceuticals, vol. 17, no. 12, 2024, https://doi.org/10.3390/ph17121713.